Analyst
Zelman & Associates
Equibles does not estimate personal net worth.
Get an email with a short summary when TriSalus Life Sciences, Inc. publishes a filing, an earnings call transcript or a press release.
Get TLSI alertsAlex Kim is recorded as Analyst at Zelman & Associates, COO at Standard Biotools Inc. (LAB) since April 4, 2022 and CFO at Standard Biotools Inc. (LAB). The newest filing on record that lists Alex Kim as CFO at Standard Biotools Inc. (LAB) is dated April 27, 2026. Standard Biotools Inc. reported in an 8-K filed November 7, 2024 that Alex Kim was appointed Chief Financial Officer, effective November 11, 2024. Standard Biotools Inc. reported in an 8-K filed July 31, 2024 that Alex Kim was appointed Interim Chief Financial Officer, effective September 1, 2024. The proxy statement of Standard Biotools Inc. reports total compensation of $4,005,165 for Alex Kim in fiscal 2025, including a base salary of $496,724. Disclosed compensation is on record for 4 fiscal years. Alex Kim has spoken on 14 earnings calls and 1 other investor event across 7 companies, most recently for Camden Property Trust on July 31, 2026. Those appearances were for Camden Property Trust (CPT), Standard Biotools Inc. (LAB), Mid America Apartment Communities Inc. (MAA), Vivmark Residential (VMRK), UDR, Inc. (UDR) and 2 other companies. Standard Biotools Inc. is classified in the Medical Devices industry within the Healthcare sector. TriSalus Life Sciences, Inc. is classified in the Medical Devices industry within the Healthcare sector. Other companies whose calls Alex Kim spoke on are classified in the Real Estate sector. Other leadership on record at Standard Biotools Inc. includes Dr. Josh Bilenker (CEO), Dr. Michael Egholm (CEO), Michael Egholm (CEO and Board Member) and 7 others.
“On November 6, 2024, the Board of Directors of Standard BioTools Inc. (the "Company") appointed Alex Kim, who has been serving as the Company's Interim Chief Financial Officer since September 1, 2024, as the Company's fulltime Chief Financial Officer, effective as of November 11, 2024 (the "Effective Date").”
“On July 30, 2024, the Company's Board of Directors appointed Alex Kim, the Company's Chief Operating Officer, to serve as Interim Chief Financial Officer of the Company, starting on September 1, 2024, to succeed Mr. Black while the Company searches for a permanent Chief Financial Officer.”
“I wanted to ask about development lease-up velocity, just curious how that's going in the two projects that you guys have in lease-up, and how are rents and concessions tracking relative to underwriting, and then just potentially what are the expected stabilization yields?”
“I wanted to drill a little further into the same storage expense growth guide um you know to reduce by 90 basis points at the net point you know i'm curious how much of the improvement reflects sustainable operating efficiencies versus timing items and i was wondering if you could discuss the outlook for some of the…”
“I was wondering if you could just maybe touch on the Prop 13 impact. I know you've got a $50 million sort of placeholder here. you know, is that applicable, you know, to just one of the two companies?”
“I wanted to ask a little about the development environment today and some of the economics that you're seeing particularly in relation to kind of your capital allocation strategy you know where does development sit in relative to acquisitions and then you know potentially looking at share repurchases and then you know…”
“I wanted to focus a little bit on San Francisco, which you've highlighted as a standout market.”
2022-04-04–present
Source not stated
Zelman & Associates
Analyst
Transcript header (unverified)
Start not stated–present
Last confirmed April 27, 2026
Medical Devices · Healthcare
CFO, COO
2022-04-04–present
VMRK
REIT - Residential · Real Estate
UDR
REIT - Residential · Real Estate
Avalonbay Communities Inc
REIT - Residential · Real Estate
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Standard Biotools Inc. (LAB) | Chief Financial Officer | $496,724 | $4,005,165 |
| 2024 | Standard Biotools Inc. (LAB) | Chief Financial Officer | $485,000 | $3,090,340 |
| 2023 | Standard Biotools Inc. (LAB) | Chief Financial Officer | $430,000 | $909,788 |
| 2022 | Standard Biotools Inc. (LAB) | Chief Financial Officer | $298,485 | $5,856,938 |
Avalonbay Communities Inc Q4 FY2025 Earnings Call
Avalonbay Communities Inc
